Do current economic evaluations fully capture vaccine value: a review of evidence from India.

IF 1.8 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-18 DOI:10.1080/14737167.2024.2417767
Navneet Kaur, Joseph L Mathew, Madhu Gupta, Jacob John, Shankar Prinja
{"title":"Do current economic evaluations fully capture vaccine value: a review of evidence from India.","authors":"Navneet Kaur, Joseph L Mathew, Madhu Gupta, Jacob John, Shankar Prinja","doi":"10.1080/14737167.2024.2417767","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Traditional economic evaluations typically focus on direct health effects and costs offset to the healthcare system. However, vaccines offer significant indirect benefits beyond direct health effects, such as herd immunity, reduced force of infection, reduction in antimicrobial resistance, and others. Failure to consider these benefits while evaluating vaccines may undervalue vaccines. Therefore, it is argued that the full value of vaccines should be estimated by incorporating these broader benefits.</p><p><strong>Areas covered: </strong>This review presents the broader value domains proposed in literature by various frameworks, and their definitions. The review of economic evidence of vaccine use in India to discuss to what extent these broader value domains have been considered in economic evaluations in India has been presented. We also discuss specific considerations that need to be taken care of while developing value frameworks or guidelines for the economic evaluation of vaccines.</p><p><strong>Expert opinion: </strong>To develop a comprehensive framework tailored to the country needs, prioritize relevant value domains and optimal methodologies based on the country's healthcare context, and data availability. These value domains must align with people's as well as decision-makers preferences to ensure economic assessments are relevant and actionable.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2024.2417767","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Traditional economic evaluations typically focus on direct health effects and costs offset to the healthcare system. However, vaccines offer significant indirect benefits beyond direct health effects, such as herd immunity, reduced force of infection, reduction in antimicrobial resistance, and others. Failure to consider these benefits while evaluating vaccines may undervalue vaccines. Therefore, it is argued that the full value of vaccines should be estimated by incorporating these broader benefits.

Areas covered: This review presents the broader value domains proposed in literature by various frameworks, and their definitions. The review of economic evidence of vaccine use in India to discuss to what extent these broader value domains have been considered in economic evaluations in India has been presented. We also discuss specific considerations that need to be taken care of while developing value frameworks or guidelines for the economic evaluation of vaccines.

Expert opinion: To develop a comprehensive framework tailored to the country needs, prioritize relevant value domains and optimal methodologies based on the country's healthcare context, and data availability. These value domains must align with people's as well as decision-makers preferences to ensure economic assessments are relevant and actionable.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
当前的经济评估是否充分体现了疫苗的价值:印度证据回顾。
导言:传统的经济评估通常侧重于对健康的直接影响和医疗系统的成本抵消。然而,除了直接的健康影响外,疫苗还能带来巨大的间接益处,如群体免疫、降低感染力、减少抗菌素耐药性等。如果在评估疫苗时不考虑这些益处,可能会低估疫苗的价值。因此,有观点认为,疫苗的全部价值应通过纳入这些更广泛的益处来估算:本综述介绍了各种框架在文献中提出的更广泛的价值领域及其定义。通过回顾印度疫苗使用的经济证据,讨论印度的经济评估在多大程度上考虑了这些更广泛的价值领域。我们还讨论了在为疫苗经济评估制定价值框架或指南时需要注意的具体事项:专家意见:为制定符合国家需求的综合框架,应根据国家的医疗保健背景和数据可用性,优先考虑相关价值领域和最佳方法。这些价值领域必须符合人们以及决策者的偏好,以确保经济评估具有相关性和可操作性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Expert Review of Pharmacoeconomics & Outcomes Research
Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY
CiteScore
4.00
自引率
4.30%
发文量
68
审稿时长
6-12 weeks
期刊介绍: Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.
期刊最新文献
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 - 2020. Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell or solid organ transplantation - a perspective of the German healthcare system. Content and cost of waste pharmaceuticals collected by pharmacies for disposal. Correction. Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1